Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia.
Chutima Kumkhaek; James G Taylor; Jianqiong Zhu; Carolyn Hoppe; Gregory J Kato; Griffin P Rodgers (Profiled Author: Gregory Kato)
Molecular and Clinical Hematology Branch, NIDDK, NIH, Bethesda, MD, USA.
British journal of haematology 2008;141(2):254-9.
The hydroxycarbamide (HC)-inducible small guanosine triphosphate (GTP)-binding protein, secretion-associated and RAS-related (SAR) protein has recently been shown to play a pivotal role in HBG induction and erythroid maturation by causing cell apoptosis and G1/S-phase arrest. Our preliminary analysis indicated that HC inducibility is transcriptionally regulated by elements within the SAR1A promoter. This study aimed to assess whether polymorphisms in the SAR1A promoter are associated with differences Hb F levels or HC therapeutic responses among sickle cell disease (SCD) patients. We studied 386 individuals with SCD comprised of 269 adults treated with or without HC and 117 newborns with SCD identified from a newborn screening program. Three previously unknown single nucleotide polymorphisms (SNPs) in the upstream 5'UTR (-809 C>T, -502 G>T and -385 C>A) were significantly associated with the fetal haemoglobin (HbF) response in Hb SS patients treated with HC (P < 0.05). In addition, four SNPs (rs2310991, -809 C>T, -385 C>A and rs4282891) were significantly associated with the change in absolute HbF after 2 years of treatment with HC. These data suggest that variation within SAR1A regulatory elements might contribute to inter-individual differences in regulation of HbF expression and patient responses to HC in SCD.
Scientific Context
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Related Publications
-
1.
1995S Charache; M L Terrin; R D Moore; G J Dover; R P McMahon; F B Barton; M Waclawiw; S V Eckert
Controlled clinical trials 1995;16(6):432-46. -
2.
1996S Charache; F B Barton; R D Moore; M L Terrin; M H Steinberg; G J Dover; S K Ballas; R P McMahon; O Castro; E P Orringer
Medicine 1996;75(6):300-26. -
3.
2008Sophie Lanzkron; John J Strouse; Renee Wilson; Mary Catherine Beach; Carlton Haywood; HaeSong Park; Catherine Witkop; Eric B Bass; Jodi B Segal
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
Annals of internal medicine 2008;148(12):939-55.

Appears in this Publication









